We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Test Detects Premature Rupture of Fetal Membrane

By HospiMedica staff writers
Posted on 29 Oct 2003
A new test detects the premature rupture of fetal membrane (PROM), which occurs in around 10% of pregnant women, influencing pre- and postnatal morbidity and mortality.

PROM occurs when a pregnant woman's amniotic fluid sac breaks prematurely and is not followed by labor in 24-48 hours. More...
About 30% of pregnant women are checked for PROM. If the rupture of the amniotic sac, which causes leakage of amniotic fluid, is not detected and treated in a timely manner, serious complications for the neonate and the mother may occur.

The test, called AmniSure, detects premature fetal membrane rupture. No reliable diagnostic for PROM exists today, states N-Dia, Inc. (Boston, MA, USA), which developed the test. The company believes that current tests (nitrazine test or ferning, for example) date from the 1950s and are both inaccurate and invasive (requiring a mandatory speculum examination). In contrast, AmniSure is a rapid noninvasive strip test that provides an answer in a few minutes, whether used in a clinic or at home.

N-Dia is a medical device company developing diagnostic products based on its research in cellular biology. These products utilize proprietary monoclonal antibodies against specific proteins associated with particular disorders and diseases. The company has developed a method that allows a diagnostic device to detect very small quantities of these proteins. The company states that this permits early and accurate detection of a dangerous medical condition and provides the possibility of timely treatment.




Related Links:
N-Dia

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.